EMD Serono Research & Development Institute
Trial Pipeline
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
NCT07360314
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
NCT07166601
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
NCT06421935
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
NCT05882734
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
NCT05396833
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
NCT04170153
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
NCT03940703
Avelumab Program Rollover Study
NCT03815643
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992
Bintrafusp Alfa Program Rollover Study
NCT05061823
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
NCT04882917
The MS-LINK™ Outcomes Study
NCT04735406
M1231 in Participants With Solid Tumors
NCT04695847
Tepotinib Hepatic Impairment Trial
NCT03546608
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
NCT03284970
First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
NCT02644278
Oral Cladribine in Early Multiple Sclerosis (MS)
NCT00725985
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 4 |
| Phase 3 | 3 |
Therapeutic Areas
What the Pipeline for EMD Serono Research & Development Institute Shows
According to the ClinicalTrials.gov registry, EMD Serono Research & Development Institute is linked to 51 US clinical trials across every stage of research activity. Of those, 34 studies are currently recruiting — about 67% of the sponsor's indexed portfolio — and 8 are already marked complete, representing roughly 16% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for EMD Serono Research & Development Institute reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 45 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for EMD Serono Research & Development Institute is Advanced Solid Tumor with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.